Understanding PARP2's Role in DNA Repair and Cancer Treatment Side Effects
The non-catalytic function of PARP2 in DNA repair and cancer therapy
This research aims to understand why certain cancer treatments, called PARP inhibitors, sometimes cause severe anemia and other blood problems in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11126568 on NIH RePORTER |
What this research studies
PARP inhibitors are important medicines for some breast, ovarian, pancreatic, and prostate cancers. While these drugs are effective, about one-third of patients experience severe anemia, which can lead to lower doses or stopping treatment early. This project is looking into a specific protein called PARP2 to figure out why these side effects happen. By understanding how PARP2 works beyond its main job, we hope to find ways to make cancer treatments safer and more effective for patients.
Who could benefit from this research
Good fit: Patients currently receiving or considering PARP inhibitor therapy for cancers like breast, ovarian, pancreatic, or prostate cancer, especially those experiencing or at risk for anemia, might benefit from future applications of this research.
Not a fit: Patients not undergoing PARP inhibitor therapy or those with cancers not treated by these specific drugs may not directly benefit from this particular line of research.
Why it matters
Potential benefit: If successful, this work could lead to new strategies to reduce severe side effects like anemia in cancer patients receiving PARP inhibitor therapy, allowing them to continue treatment more effectively.
How similar studies have performed: PARP inhibitors are already successfully used in treating several cancers, but this research explores a novel aspect of their mechanism to address unexpected side effects.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Zha, Shan — Columbia University Health Sciences
- Study coordinator: Zha, Shan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.